Hyperoxaluria

20 registered clinical trials studyying Hyperoxaluria — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in C NCT06578754	Western Galilee Hospital-Nahariya	—
Completed	A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk. NCT06481150	University of Texas Southwestern Medical Center	Phase 4
Unknown	Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients NCT05443932	Medical University of Vienna	Phase 4
Withdrawn	A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria NCT06138327	BioMarin Pharmaceutical	Phase 1
Completed	Plasma Oxalate in Patient With Short Bowel NCT04119765	Hospices Civils de Lyon	—
Completed	Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate NCT04571359	Aga Khan University	—
Completed	Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children NCT04756024	Aga Khan University	—
Completed	A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria NCT03095885	Allena Pharmaceuticals	N/A
Recruiting	Prospective Research Rare Kidney Stones (ProRKS) NCT02780297	Mayo Clinic	—
Completed	Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidne NCT02547805	Allena Pharmaceuticals	Phase 2
Completed	Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones NCT02503345	Allena Pharmaceuticals	Phase 2
Completed	Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk NCT02404701	University of Wisconsin, Madison	N/A
Completed	Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hypero NCT02289755	Allena Pharmaceuticals	Phase 2
Completed	Hydroxyproline Influence on Oxalate Metabolism NCT02038543	Mayo Clinic	Phase 1 / Phase 2
Completed	Oxazyme in Patients With Hyperoxaluria NCT01127087	Mayo Clinic	Phase 1 / Phase 2
Withdrawn	Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria NCT00280215	Mayo Clinic	Phase 3
Completed	Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria NCT00283387	Mayo Clinic	Phase 2
Completed	Use of Oral Probiotics to Reduce Urinary Oxalate Excretion NCT00587041	Mayo Clinic	Phase 1 / Phase 2
Completed	Proteomic Study of Urinary Stone Disease NCT00199459	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	—
Completed	Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria NCT00588120	Mayo Clinic	Phase 1